Holistically Addressing Bottlenecks and Attrition Rates in Drug Development
Holistically addressing bottlenecks and attrition rates in drug development
Since the turn of the century, the pharmaceutical industry has seen dramatic changes, including dwindling drug pipelines, looming patent expirations and rising costs.
The improved access to high-quality data and the development of powerful in silico tools have helped researchers to better understand the underlying mechanisms of disease and predict the behavior of compounds in vivo, improving the outcome of various stages of the pharmaceutical R&D. However, to truly overcome the challenges faced by the industry, innovative approaches are needed to all aspects of the drug development process.
This white paper looks at some key aspects of early drug development that are ripe for innovation, with high potential for addressing the issues of the industry.
To access the complimentary white paper 'Holistically addressing bottlenecks and attrition rates in drug development', please fill in the form below.
By submitting this form you also agree to receive information relevant to your interests from Elsevier B.V. and its affiliates worldwide. You can opt-out at any time by following the instructions given in the email messages you receive.
Elsevier's R&D Solutions supporting 'Holistically addressing bottlenecks and attrition rates in drug development'
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.